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ABSTRACT   
Objective: Although diffuse systemic sclerosis (SSc) is associated with a reduction in 
life expectancy, there are no validated, prognostic models for 5-year mortality in diffuse 
SSc.  The objective of this study was to derive and validate a 5-year mortality prediction 
rule for early diffuse SSc patients.   
Methods: We used an inception cohort of 388 Caucasian US patients with early diffuse 
SSc (< 2 years from the first symptom).   Predefined baseline variables were entered into 
a stepwise logistic regression model to identify factors independently associated with 5-
year all-cause mortality.  After rounding the beta-weights to the nearest integer, and 
summing them, we stratified patients into low (<0 points), moderate (1-2 points) and 
high-risk (≥ 3 points) groups.  We then applied this rule to an external validation cohort 
of 110 Caucasian early diffuse SSc patients from the Royal Free Hospital cohort and 
compared stratum-specific 5-year mortality. 
Results:  Six independent predictors (rounded beta-weight) comprised the model: age at 
first visit (-1, 0, 1), male gender (0,1), tendon friction rubs (0,1), gastrointestinal 
involvement (0,1), RNA polymerase III antibody (0,1) and anemia (0,1).  The 3-level risk 
stratification model performed well with no significant differences between the US 
derivation (AUC =0.73 (95% CI 0.69–0.78) ) and UK (AUC= 0.69 (95% CI 0.61–0.77)) 
validation cohorts.   
Conclusion: We have derived and externally validated in US and UK cohorts an easy-to-
use 6-variable prediction rule that assigns low, moderate and high risk categories for 5-
year mortality in early diffuse SSc patients.   Only history, exam and basic labs are 
required.   
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INTRODUCTION 
Systemic sclerosis (SSc) is a multisystem autoimmune disease with a heterogeneous 
clinical presentation and disease course, but the highest case specific mortality among the 
rheumatic diseases(1).   Given this varied clinical course in SSc, it is important to identify 
patients at high risk for mortality from a clinical and research perspective.   Risk 
assessment is of particular relevance in the context of new emerging therapies and recent 
advances in autologous hematopoietic stem cell transplantation, for which there may be 
substantial treatment-related mortality but improved long-term outcomes in subgroups of 
SSc patients.   
 
Published estimates of 5-year mortality range from 5-65% in the medical literature (2-
12), with a lower survival in the diffuse cutaneous SSc subtype consistently reported.   
Dissimilar survival is not surprising given the natural history of disease in the diffuse and 
limited cutaneous subtypes.  Patients with diffuse cutaneous SSc tend to accumulate 
internal organ involvement very early in their disease, whereas those with limited 
cutaneous disease may develop new organ involvement even decades after onset (13). 
This distinction in natural history is important because it is likely that there are different 
significant contributors to mortality risk in limited and diffuse SSc patients.  Thus, we 
feel that the cutaneous subtypes should be considered separately in SSc mortality 
modeling, particularly in early disease (9).  
 
There have been two validated 5-year mortality models published in SSc.  The first (14) 
is a 5-factor model derived and validated in 5 Italian centers.  The second (15) used the 
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European (EUSTAR) population to validate a 5-factor model originally published by 
Bryan et al. in 1996, using a UK population(1). Both of these models combined limited 
and diffuse SSc patients.  The first assessed 5-year mortality from first physician 
diagnosis, and the second from SSc onset (defined as first non-Raynaud symptom).  
These definitions introduce potential bias by including variable amounts of times prior to 
the observational period in the mortality model.   
 
As advances have been made in SSc diagnosis, clinical care and treatments, there has 
been an emphasis on multi-center and international collaborative research.  This is 
exemplified by reports published by the EUSTAR group and therapy trials in which the 
vast majority of patients came from centers participating in the Scleroderma Clinical 
Trials Consortium (SCTC). With this in mind it is important to test prognostic prediction 
models in novel populations where performance can decline. Therefore, we sought to 
validate our US model in a United Kingdom (UK) SSc population.   
 
The objective of this study was to derive and validate a prediction rule for 5-year in 
patients with early diffuse SSc.  We strove to develop a bedside-friendly risk 
stratification tool that could be used at the first rheumatology or SSc clinic visit.  To 
address biases in prior mortality studies, we used a prospectively followed inception 
cohort of patients with early diffuse SSc to derive the model.  We then performed an 
external validation in a prospectively followed cohort of early diffuse SSc patients from 
the UK.    
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METHODS 
Patient Selection 
Derivation cohort (Pittsburgh):  We prospectively identified an inception cohort of adult 
early diffuse SSc patients seen for a first visit at the UPMC and University of Pittsburgh 
Scleroderma Center between January 1, 1980 and December 31, 2008. We defined early 
diffuse SSc at the first visit as:  SSc presenting within two years from the first symptom 
attributable to SSc (including Raynaud phenomenon), and the presence of diffuse skin 
thickening at the first visit (i.e. skin thickening proximal to the elbows and knees).  All 
patients had provided informed consent to participate in our institutional observational 
SSc prospective cohort study.   To ensure accurate assessment of vital status, we 
excluded individuals who were not US citizens or did not reside in the United States.     
 
To be included in the derivation cohort all diffuse SSc patients were required to have a 
complete history, physical examination, and sufficient clinical and laboratory objective 
testing to accurately assess organ involvement and severity.  Since the overall percentage 
of non-Caucasians in our sample was < 7%, we restricted the derivation sample 
population to Caucasians to reduce model variability, and that we felt future genetic 
information could be added later to improve model performance.   
 
External validation cohort (Royal Free). We used patients included the Royal Free 
Hospital scleroderma research database to externally validate our prognostic model.   We 
applied the same inclusion criteria to identify a validation cohort of adults with early 
diffuse SSc seen at the Royal Free Hospital for an initial visit between January 1, 2000 
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and December 31, 2008. All of the Royal Free patients had previously provided informed 
consent to participate a longitudinal study of SSc outcome at their institution.   
 
Baseline data 
Pittsburgh derivation cohort.  For all Pittsburgh patients, one of three rheumatologists 
(Drs. Medsger, Steen or Domsic) completed an initial visit data collection form, which 
included demographics, date of symptom onset, date of organ system involvement using 
objective criteria, other medical history, tobacco use, physical examination findings and 
the following objective test results: chest radiograph or high resolution chest computer 
tomography (HRCT), pulmonary function tests (PFTs),  echocardiogram, EKG, cine 
esophagram or esophageal manometry, hemoglobin, erythrocyte sedimentation rate 
(ESR), serum creatine phosphokinase (CPK) and SSc-associated serum autoantibody.  
Royal Free validation cohort.  For all patients an initial visit data collection form had 
been previously completed at the time of visit.  This included demographics, physical 
examination findings, objective GI and cardiopulmonary testing and laboratory results 
which included hemoglobin and SSc-associated serum antibody testing.   Medical records 
were reviewed to minimize missing data. 
 
Candidate predictor variables 
We identified candidate predictor variables by reviewing the literature on SSc prognosis 
and included all variables that had been reported as significantly associated with 
mortality.   Candidate predictor variables were then grouped into five categories: 1) 
patient demographics and referral characteristics (i.e., age, gender, referral area, decade 
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of presentation (1-5, 7, 8, 10, 12, 16-24); 2) medical history, i.e., disease duration, 
presence of another connective tissue disease (overlap syndrome), tobacco use, 
hypertension, diabetes mellitus, heart disease, obesity, medication use (12, 25); 3) 
physical examination findings i.e., the modified Rodnan skin score (mRss), mRss >20 
(26), skin thickness progression rate (STPR) calculated by dividing the mRss by the time 
since onset of skin thickening in years (27), presence and number of tendon or bursal 
friction rubs, presence of digital ulcers (28); 4) laboratory findings (anti-RNA polymerase 
III antibody, anti-topoisomerase I antibody, hemoglobin, ESR (1, 4, 5, 10-12, 16, 17, 21, 
29); and 5) organ involvement i.e. lung disease, renal crisis, cardiac, gastrointestinal, 
skeletal muscle, joint/tendon, pulmonary hypertension, peripheral vascular (2-5, 8, 16-19, 
21, 23-25, 30, 31).   
 
Organ involvement was quantitated using two classification methods: present or absent 
(27), and severity (21).  The presence of organ system involvement presence was 
classified in the following manner:  1) lung (fibrosis on chest x-ray or high resolution 
chest CT or abnormal PFTs with FVC < 70% with a normal FEV1/FVC ratio); 2) renal 
(clinical evidence of renal crisis defined as the abrupt onset of accelerated arterial 
hypertension or rapidly progressive oliguric renal failure); 3) cardiac (pericarditis, 
myocarditis, arrhythmia requiring treatment or complete heart block); 4) gastrointestinal 
(distal esophageal dysmotility by esophagram or manometry, evidence of hypomotility of 
the duodenum or small intestine on imaging or manometry, small bowel bacterial 
overgrowth requiring antibiotics, gastric antral vascular ectasia, wide-mouthed colonic 
sacculations, pseudoobstruction, physician judgment of malabsorption syndrome, or 
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heartburn plus distal dysphagia for solid foods); 5) muscular (proximal muscle weakness 
on physical exam with elevated serum CPK > 2 times normal, myopathic changes on 
electromyogram or abnormal muscle biopsy); 6) articular (joint swelling or contractures, 
palpable tendon friction rubs or joint space narrowing or erosions on radiograph); 7) 
pulmonary arterial hypertension (PAH) defined as mean pulmonary artery pressure > 25 
mmHg on cardiac catheterization and not attributable to ILD or cardiac involvement; and 
8) vascular (Raynaud phenomenon or the presence of digital pitting scars, digital tip 
ulceration or digital gangrene). 
 
We used the Medsger severity scale to quantify the severity of internal organ 
involvement, which uses a scale from 0 (no involvement) to 4 (end-stage) in 8 different 
organ systems.  We used the SSc expert consensus “modified” version of this scale (21) 
in our analysis.  Lung involvement was classified and analyzed separately as: 1) a fibrosis 
component using FVC and positive radiographic imaging, and 2) a pulmonary 
hypertension component for two reasons.  First, the pathology of these complications is 
different, as one is primarily fibrotic and the other a vasculopathy.  Secondly, the natural 
history of these complications is different, particularly in patients with early diffuse 
scleroderma (13).  Renal disease was classified as no involvement/mild disease and 
moderate/severe disease as there was only one patient with mild severity. Given the low 
frequencies of high severity scores, we classified the remainder of organ severity as none, 
mild or moderate/severe/end-stage (3 stages combined) involvement.  We did not use the 
cardiac severity index as a predictor variable due to low frequency of transthoracic 
echocardiogram ascertainment during the early years of this cohort.    
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Outcomes 
We developed our prognostic model to predict 5-year, all-cause mortality from the time 
of the first Scleroderma Center visit.  Vital status was determined as of December 31, 
2013 using the U.S. Social Security Death Index for the Pittsburgh cohort.  For the Royal 
Free cohort, vital status as of May 1, 2014, was determined using the UK National Care 
Record Service.   
 
Model derivation 
We first performed bivariate analysis of the predefined candidate predictor variables at 
the first visit using 5-year all-cause mortality as the dependent variable.   All candidate 
predictor variables with a p-value ≤ 0.20 on bivariate analysis were then placed into a 
stepwise multivariable logistic regression model with a p-value ≤ 0.05 required to remain 
in the model.  Regression diagnostics were performed and goodness of fit assessed.  To 
generate a simple integer point score that would be easy to calculate, the logistic 
regression model coefficients were rounded to the nearest 1.0.  A total point score for 
each patient was then calculated by summing the rounded beta-weights.   Using the 
summed score, patients were assigned to one of three risk categories for two-year 
mortality based on distribution: low (≤ 0 points), moderate (1-2 points) or high (≥3 
points).  We performed the model derivation in accordance with previously published 
methodologic standards for clinical risk prediction model development (32).   
 
Model validation 
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In the validation cohort we evaluated missing data.  There were four areas in which there 
was some missing data and these included the recording of tendon friction rubs, objective 
GI testing,  hemoglobin and RNA polymerase III antibody testing.  We did not feel that 
the recording of tendon friction rubs and ordering objective GI testing was at random, as 
it was likely that they were not recorded or ordered because the symptoms or findings 
were absent.   Thus, we evaluated missing data with two methods.  First, we assumed that 
all missing elements were negative or not present.  Second, multiple data imputations 
were performed for hemoglobin and antibody testing, as these were felt to be missing at 
random.  All statistical analysis was completed using SAS version 9.3 software (SAS, 
Cary, NC).     
 
We constructed a receiver operating characteristic (ROC) curve  of the prediction rule 
with the area under the ROC (AUC) calculated as a measure of model discrimination 
(33).  The model developed in the Pittsburgh cohort was then applied to the Royal Free 
cohort and an AUC calculated. The performance of the total integer score and associated 
three-level risk stratification was then evaluated using two methods.  First, we compared 
stratum-specific mortality rates in the derivation and validation cohorts within each of the 
three risk classes using chi-square statistics.  Next, we compared the exact AUC for 
predicting mortality using each of the three risk classes as cut-points in the derivation and 
validation cohorts.  Stratum-specific chi-square analysis was then performed between the 
derivation and validation cohorts.   
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RESULTS 
Pittsburgh Derivation cohort.  Of the 2879 SSc patients first evaluated at the University 
of Pittsburgh Scleroderma Center between 1980 and 2007, 1304 had diffuse disease, of 
which 805 presented within two years of symptom onset.  Of the 688 Caucasian adults 
with early diffuse SSc who lived in the US, 388 (56%) had the laboratory and objective 
testing required to assess organ system involvement at or within 60 days of their initial 
visit and comprised our final study cohort  (Figure 1).   There was no difference in 
demographics, disease characteristics, laboratory findings or mortality between the 388 
with complete objective testing and the 300 without.   In the final population of 388, there 
was minimal missing data.  Missing data included: ESR (20%), hemoglobin (3%), 
autoantibody (4%) and body mass index (38%).   We categorized age at the first visit into 
five groups (<35, 35-44, 45-54, 55-64, >65 years) based upon prior SSc literature (18, 34, 
35).     
 
Royal Free validation cohort.  Of 160 early diffuse SSc patients seen for an initial visit 
between the years 2000 and 2008, 144 were Caucasian and formed the external UK 
validation cohort.   
 
Baseline patient characteristics 
The overall Pittsburgh cohort of 388 patients was 76% female, had a mean age of 50.4 (± 
13.3) years were first evaluated a median of 0.93 (0.63, 1.33) years after the first SSc 
symptom.  Sixty-one (16%) were current and 34% prior smokers.  141 (36%) lived within 
100 miles of Pittsburgh (our typical referral area).  At the first visit, 209 (53%) had 
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evidence of gastrointestinal involvement, 108 (28%), lung involvement, 79 (21%) cardiac 
involvement and 62 (16%) renal crisis.  Overall, 209 (56%) were RNA polymerase III 
antibody positive, and 91 (24%) were anti-topoisomerase I antibody positive.   
 
The only statistically significant differences in baseline demographics between the 
Pittsburgh and Royal Free cohorts (Table 1) was the median disease duration at first visit,  
which was slightly longer at 1.02 (0.78, 1.45) years in the Royal Free cohort, and may 
reflect the difference in referral patterns and operation in two different healthcare 
systems. There were no differences in baseline medical history and total skin score, but 
the distribution of STPR was different between the cohorts, with the Royal Free having 
more patients with a slow STPR. The Pittsburgh cohort also had more patients with 
tendon friction rubs and RNA polymerase III antibody, which may explain the lower 
percentage of slow STPR compared to the Royal Free cohort.  There was no difference in 
baseline visit organ system involvement. BMI and cardiac involvement based on 
arrhythmia were not consistently available for the Royal Free cohort, and thus could not 
be assessed.   
 
Survival 
At five years of follow-up from the first visit, 110 (28%) of Pittsburgh patients had died.  
In the Royal Free cohort 29 (26%) had died at five years.  There was no difference 
(p=0.65) in 5-year mortality between the cohorts.   
 
Derivation of the prediction rule 
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 In bivariate analyses, we identified 18 baseline variables significantly associated with 5-
year mortality (Table 2), including two demographic factors (age, gender), two history 
variables (referral area, decade of presentation), four physical examination findings 
(mRss, STPR, presence and number of tendon friction rubs), three laboratory 
abnormalities (anti-topoisomerase I positivity, anti-RNA polymerase III positivity, 
anemia), and the presence or absence of involvement of four organ systems (lung, renal 
crisis, cardiac and GI), and severity of involvement of four organ systems (lung, GI, 
skeletal muscle and skin).   The odds ratios for these variables ranged from 0.43 to 4.79.   
 
In the multivariable analysis, six factors were independently associated with 5-year 
mortality including:  (1) age at first visit; (2) male gender; (3) tendon friction rubs;  (4) 
GI involvement; (5) anti-RNA polymerase III antibody; and (6) anemia (Table 3).  The 
AUC for the derivation cohort was 0.79 (95% CI 0.74 – 0.84) using the original beta 
values of these six variables.    
 
When the beta values were rounded to the nearest one (Table 3) in the Pittsburgh 
derivation cohort,  63 patients (25%) were low risk (≤0 points) and had a mortality rate of 
1.6%; 108 (43%) were intermediate risk (1-2 points) with a mortality rate of 14.8%, and 
81 (32%) were high risk (≥3 points) and had a mortality rate of 49.4% (Table 4). The 
AUC for this 3-level risk stratification tool is 0.73 (95% CI 0.69 – 0.78) 
 
Validation of the risk stratification model   
The derivation and validation of a 5-year mortality rule for diffuse scleroderma 
domsicr Page 15 7/14/2016 
When the 6-variable points were summed in the Royal Free cohort, 50 patients (35%) 
were low risk, 78 patients (54%) moderate and 16 (11%) high risk.  The mortality rates 
for patients in these risk stratification levels were 3%, 18% and 50%, respectively (Table 
4).    In the stratum-specific analysis comparing the derivation and validation cohorts, 
there were no differences in mortality in the low (p=0.72), moderate (p=0.47), or high 
risk classes (p=0.39).  The area under the ROC curve for the Royal Free cohort was AUC 
=0.68 (95% CI 0.59 – 0.77), which was not different from the Pittsburgh cohort (p=0.19) 
using the three risk classes.    When multiple data imputation for hemoglobin and anti-
RNA polymerase III was performed the AUC was 0.69 (95% CI 0.61 – 0.77), which was 
not different from the Pittsburgh cohort (p=0.35, Figure 4) 
 
DISCUSSION 
We derived and internally and externally validated a prediction model to risk-stratify 
adult Caucasian patients with early diffuse SSc for 5-year mortality.  To develop this 
model, we used an inception cohort of patients, and carefully applied methodologic 
standards for risk prediction rule development.  The result is a simple, six-factor model 
that can be easily used to accurately risk stratify patients at the bedside, requiring only 
history, physical examination and standard available laboratory variables.    
 
Only two prior studies have performed internal or external validation in 5-year mortality 
models in SSc.  Beretta et al. (14) published a paper in which multiple regression 
modeling techniques and data mining based classifiers were used to develop a 5-year 
prognostic model in Italian patients with SSc from the time of diagnosis.  An external 
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cross-validation was then performed on 356 patients from 5 different Italian centers.  The 
final five-factor model seemed to perform well, although actual statistical comparisons 
between the original and validation samples were not reported, and the model is 
somewhat cumbersome to use at the bedside.  Fransen et al. (15) externally validated a 5-
year mortality model originally published by Bryan et al. in 1996 (1). The Bryan model 
was developed in 260 patients from a single UK center who were followed for five years 
after SSc disease onset.  This was a five-factor model composed of age, gender, ESR, 
carbon monoxide diffusing capacity (DLCO) and presence of urine protein.  The AUC 
was not reported in the Bryan paper, but showed good discriminatory ability in the 
Fransen external validation cohort (AUC = 0.78) when the original beta-estimate weights 
were used.  When a clinically useful tool was created by adding the number of risk 
factors together as originally proposed by Bryan, performance appeared to diminish in 
the validation cohort, although true accuracy is unknown as the AUC was not reported. 
The poorer performance is likely related to the significantly lower mortality rate in the 
Fransen validation cohort (11%) compared to the Bryan derivation cohort (28%).  Both 
the Beretta and Fransen reports combined limited and diffuse cutaneous SSc patients, and 
both used prevalent rather than inception cohorts, which introduces multiple left-
censoring biases to be considered in applying the results.   Our model is designed 
specifically for patients with clearly defined early diffuse SSc, and was developed in an 
inception cohort of SSc patients to reduce bias.  Finally, the 5-year mortality prediction 
starts from the time of first SSc diagnosis in Beretta’s manuscript, and from SSc onset 
(defined as first non-Raynaud symptom) in the Fransen and Bryan papers. Our model is 
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designed for the first SSc center visit, which we feel is easily defined and relevant to 
patient care.  
 
Although we used all prospectively collected cohort data, and our derivation cohort 
contained complete data on demographics, history, examination and objective tests, there 
are potential limitations.  First, the model was developed at a single, tertiary care 
scleroderma center, and validated at another single-center scleroderma referral center.     
This may somewhat limit generalizability, although we have sought to maximize 
generalizability by choosing a validation cohort from the European continent. Second, 
this model was developed in Caucasian SSc patients only, and will need to be evaluated 
in more racially diverse populations. Third, our final cohorts were modest in size. 
Although our initial comparisons showed that there was no difference between those with 
and without objective data available, it is possible that significant unmeasured differences 
exist in these two patient groups which could have affected model performance.  Finally, 
we were not able to assess some of the newer biomarkers in this derivation cohort, such 
as CRP or genetic markers as these were not collected at the time these cohorts were 
enrolled.  However, the effect size of these biomarkers could be tested in future 
prospectively-followed cohorts of early diffuse SSc patients.   
 
Conclusions 
We derived and validated in an American and European population a simple prediction 
rule to accurately risk stratify early diffuse adult SSc patients for 5-year mortality at their 
first visit to a scleroderma center. This rule can be used by clinicians at the first 
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evaluation to risk stratify patients for early mortality when they weigh therapy decisions, 
and by researchers to identify appropriate at-risk populations for inclusion or exclusion 
criteria for clinical trials. 
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Table 1:  Baseline characteristics of the derivation and validation cohorts   
Characteristics 
Pittsburgh 
derivation 
cohort 
(n=388) 
Royal Free 
validation 
cohort 
(n=144) p-value 
Demographics 
Mean age in years at the first visit (±SD) 
 
50.4 ± 13.3 
 
52.4 ± 12.3 
 
0.31 
Gender (female)  294 (76%) 103 (72%) 0.37 
Medical History    
Disease duration at first visit in years 
(IQR) 
0.93  
(0.63, 1.33) 
1.02 
(0.78, 1.45) 
0.03 
Hypertension 20 (5%) 7 (5%) 0.89 
Coronary artery disease 5 (1%) 3 (2%) 0.69 
Diabetes mellitus 14 (4%) 1 (1%) 0.08 
Tobacco use*:                                      none 
prior use 
current use 
180/377 (48%) 
134/377 (36%) 
63/377 (17%) 
34/76 (45%)  
29/76 (38%) 
13/76 (17%) 
0.88 
Physical Examination Findings    
Mean modified Rodnan skin score (SD) 26.1 ± 11.7 25.6 ± 9.4 0.69 
Skin thickness progression rate slow  (<25) 
intermediate (25-45) 
rapid (>45) 
124 (32%) 
125 (32%) 
139 (36%) 
65 (45%) 
40 (28%) 
39 (27%) 
0.02 
Tendon friction rubs present 154 (59%) 27(22%) <0.001 
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Number of tendon friction rubs                 0 
1-3 
> 3 
101 (39%) 
79 (30%) 
80 (31%) 
83 (79%) 
19 (14%) 
13 (6%) 
0.30 
Median body mass index (IQR) 23.6 (21.2, 
26.5) 
----◊ ---- 
Internal Organ System Involvement     
Pulmonary 108 (28%) 39 (28%) 0.91 
Renal crisis 62 (16%) 19 (14%) 0.50 
Cardiac  79 (20%) ---- ---- 
Gastrointestinal  209 (54%) 66 (55%) 0.12 
Skeletal muscle  27 (7%) 6 (5%) 0.31 
Pulmonary hypertension 4 (1%) 0 0.34 
Laboratory Findings    
Anti-topoisomerase I antibody  91/384 (24%) 38/138 (27%) 0.50 
Anti-RNA polymerase III antibody  209/375 (56%) 53/123 (43%) 0.001 
Elevated erythrocyte sedimentation rate‡ 172/311 (55%) 106/135 
(79%) 
<0.001 
Anemia† 174/376 (46%) 50/137 (37%) 0.06 
*overall 43% missing data for tobacco use  
‡ defined as ESR > (age + 10)/2 for females; ESR > (age/2) for males 
†defined as hemoglobin (hgb) <12 mg/dL 
◊ not collected at first visit 
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Table 2:  Associations of baseline variables and 5-year mortality in the derivation 
cohort (bivariate analysis, n=388)   
Characteristics 
Odds 
Ratio 
95% Confidence 
Interval 
p-value 
Demographic Features    
Age  
<35  
35-44  
45-54  
55-64  
> 65 
 
-0.63 
-0.73 
---- 
0.46 
1.26 
 
0.76 
0.69 
--- 
2.26 
5.01 
<0.0001 
Male 0.55 1.73 1.06 – 2.84 
History    
Hypertension 1.39 0.54 – 3.57 0.50 
Coronary artery disease 1.70 0.28 – 10.30 0.56 
Diabetes mellitus 1.01 0.31 – 3.30 0.99 
Overlap with another connective tissue 
disease 
0.84 0.22 – 3.16 0.79 
Tobacco use 
prior vs none 
current vs none 
 
1.29 
1.75 
 
0.78 – 2.12 
0.95 – 3.21 
0.18 
 
Prednisone use                              never 
prior to first visit  
  0.85 
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prescribed at first visit 
Referral area (<100 miles from 
Pittsburgh) 
2.23 1.42 – 3.51 0.005 
Decade of diagnosis 
1990s vs 1980s 
2000s vs 1980s 
 
0.69 
0.76 
 
0.42 – 1.11 
0.39 – 1.49 
0.29 
Physical Examination Findings    
Modified Rodnan skin score 1.02 1.003 – 1.04 0.02 
Skin score > 20 (yes/no) 1.42 0.89 – 2.27 0.14 
Skin thickness progression rate      slow 
intermediate 
rapid 
 
1.22 
1.50 
 
0.69 – 2.15 
0.87 – 2.58 
0.34 
Tendon friction rubs (present or absent) 2.41 1.49 – 3.90 0.0003 
Number of tendon friction rubs 
1-3 vs 0 
> 3 vs 0 
 
1.86 
3.17 
 
1.07 – 3.25 
1.82 – 5.53 
0.002 
Mean body mass index 0.94 0.86 – 1.03 0.81 
Laboratory Findings 
Anti-topoisomerase I antibody 2.18 1.33 – 3.59 0.002 
Anti-RNA polymerase III antibody 0.42 0.26 – 0.67 0.0003 
Elevated sedimentation rate (ESR)* ,  0.65 0.40 – 1.08 0.10 
Anemia (present or absent)      Hgb < 
12 mg/dL 
2.49 1.58 – 3.92 < 0.0001 
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Degree of anemia                             
Hgb > 12 mg/dL 
Hgb 10-12 mg/dL (mild) 
Hgb < 10 mg/dL (severe) 
 
 
0.63 
0.96 
 
 
1.88 
2.62 
 0.0002 
Organ System Involvement (present/absent) 
Lung 2.10 1.31 – 3.38 0.002 
Renal crisis 1.92 1.09 – 3.37 0.02 
Cardiac 2.66 1.59 – 4.45 0.0002 
Gastrointestinal tract 2.44 1.53 – 3.89 0.0002 
Joint/tendon 4.41 1.02 – 19.15 0.05 
Skeletal muscle 2.15 0.97 – 4.75 0.06 
Pulmonary hypertension 2.55 0.36 – 18.4 0.35 
Modified Medsger Severity Score 
Interstitial lung disease                   none 
mild/moderate 
severe/endstage 
 
1.62 
3.58 
 
0.71 – 3.20 
2.17 – 13.61 
0.002 
Gastrointestinal tract                      none 
mild/moderate 
severe/endstage 
 
2.53 
6.07 
 
1.56 – 4.01 
1.64 – 22.43 
<0.001 
Joint/tendon                                    none 
mild/moderate 
severe/endstage 
 
0.61 
0.88 
 
0.35 – 1.06 
0.45 – 1.70 
0.16 
Skeletal muscle                               none   < 0.0001 
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mild/moderate 
severe/endstage 
1.81 
5.05 
1.08 – 3.04 
2.36 – 10.83 
Peripheral vascular                         none 
mild 
moderate 
severe/endstage 
 
1.23 
1.06 
1.51 
 
048 – 1.80 
0.60 – 1.85 
0.78 – 2.92 
0.63 
* ESR:greater than age/2 for males or greater than age + 10 years/2 for females 
 Hgb = hemoglobin in mg/dL 
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Table 3:  First visit multivariable associations with 5-year mortality in the 
derivation cohort (n=388).  
 
Characteristics 
 
β Odds 
Ratio 
95% 
Confidence 
Interval p-value 
Points 
Assigned 
Age at the First Visit (years)       
< 35 
35-44 
45-54 
55-64 
>65 
 
-0.58 
-0.37 
-- 
0.67 
1.42 
 
0.56 
0.69 
1.00 
1.96 
4.12 
 
0.20 – 1.53 
0.31 – 1.54 
 
0.94 – 4.10 
1.92 – 8.85 
<0.0001  
-1 
0 
0 
0 
1 
Male 0.59 1.80 1.01 – 3.20 0.05 1 
Tendon Friction Rubs 
none 
1-2 
 ≥ 3  
 
-- 
0.66 
1.21 
 
 
1.94 
3.36 
 
 
1.01 – 3.70 
1.71 – 6.59 
0.002  
0 
1 
1 
GI involvement 0.88 2.42 1.39 – 4.21 0.002 1 
RNA Polymerase III Antibody 
Positive 
-0.89 0.41 0.23 – 0.72 0.002 -1 
Anemia (<12 mg/dL) 0.77 2.17 1.25 – 3.76 0.006 1 
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Table 4: Comparison of risk class-specific 5-year mortality in the derivation and 
validation cohorts 
Risk Class 
(sum of points) 
Pittsburgh  
Derivation Cohort 
(n=388) 
Royal Free  
Validation Cohort 
(n=144) p-value 
 Deceased Deceased  
 n (%) n  (%)   
Low (≤ 0) 106 5.7 50 8.0 0.73 
Moderate (1-2) 216 28.7 78 33.3 0.47 
High (≥3) 66 63.6 16 50.0 0.39 
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Figure 1:  Patient population identification 
 
Figure 2:  Comparison of the area under the curve for the 3-level risk stratification for 5-
year mortality between the Pittsburgh and Royal Free cohorts.  
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